Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
228113-66-4CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]POMVPJBWDDJCMP-RUKDTIIFSA-MSee also: Maralixibat (has active moiety).
Breast Feeding; Lactation; Milk, Human
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine (Orphan designations)
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Maralixibat chloride
Ambiguous-DILI-concern
4
Warnings & precautions
DOI:10.1016/j.drudis.2016.02.015
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
MARALIXIBAT CHLORIDE
Ileal Bile Acid Transporter Inhibitors [MoA]; Ileal Bile Acid Transporter Inhibitor [EPC]; Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA]
BeschreibungMarilixibat chloride is an oral small-molecule ileal bile acid transporter (IBAT) inhibitor developed by Mirum Pharmaceuticals and approved by the USFDA for cholestatic pruritus in patients with Alagille syndrome (ALGS). IBAT facilitates reabsorption of bile acids from the ileum and is a key facilitator of bile acid enterohepatic recirculation. Similar to surgical interruption of enterohepatic recirculation, it was shown that inhibition of IBAT with 22 reduced pruritis in patients with ALGS.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
228113-66-4DTXSID701337104CHEMBL17879